AZN vs STAA: fair value comparison
AstraZeneca PLC and STAAR Surgical Company · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, AZN currently sits closer to the top of our ranking by discount to fair value.
| AZN | STAA | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $165.41 | $21.27 |
| 12-month range | $155.62–$209.48 | $16.10–$33.34 |
| Rank by discount to fair value | #1 of 108 Healthcare | #3 of 108 Healthcare |
| Quality grade | C | C |
| Leverage | Moderate | Low |
| Margin trend | Stable | Expanding |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Downtrend |
| DCF cross-check | Overvalued | — |
| 52-week position | The bottom quarter | The lower-middle quarter |
Full single-stock breakdowns: AZN fair value analysis · STAA fair value analysis